Michael J Kelley

List of Publications by Year
in descending order

180	8,730	81839	45285
papers	citations	39 h-index	90 g-index

186	186	186	11178
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. Journal of Clinical Investigation, 2008, 118, 3930-42.	3.9	1,225
2	A Genomic Strategy to Refine Prognosis in Early-Stage Nonâ€“Small-Cell Lung Cancer. New England Journal of Medicine, 2006, 355, 570-580.	13.9	577
3	Genomic signatures to guide the use of chemotherapeutics. Nature Medicine, 2006, 12, 1294-1300.	15.2	557
4	Induction Chemotherapy Followed by Chemoradiotherapy Compared With Chemoradiotherapy Alone for Regionally Advanced Unresectable Stage III Nonâ€“Small-Cell Lung Cancer: Cancer and Leukemia Group B. Journal of Clinical Oncology, 2007, 25, 1698-1704.	0.8	437
5	Purification and molecular cloning of a secreted, Frizzled-related antagonist of Wnt action. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 6770-6775.	3.3	387
6	A pathway-based classification of human breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 6994-6999.	3.3	306
7	T (brachyury) gene duplication confers major susceptibility to familial chordoma. Nature Genetics, 2009, 41, 1176-1178.	9.4	284
8	Implementation of Lung Cancer Screening in the Veterans Health Administration. JAMA Internal Medicine, 2017, 177, 399.	2.6	280
9	Screening for Lung Cancer*. Chest, 2003, 123, 72S-82S.	0.4	242
10	Mutation of MYH9, encoding non-muscle myosin heavy chain A, in May-Hegglin anomaly. Nature Genetics, 2000, 26, 106-108.	9.4	237
11	Human Nonsyndromic Hereditary Deafness DFNA17 Is Due to a Mutation in Nonmuscle MyosinMYH9. American Journal of Human Genetics, 2000, 67, 1121-1128.	2.6	190
12	Immunization With Mutant p53- and K-rasâ€“Derived Peptides in Cancer Patients: Immune Response and Clinical Outcome. Journal of Clinical Oncology, 2005, 23, 5099-5107.	0.8	167
13	Expression of HIF-1Î±, CA IX, VEGF, and MMP-9 in surgically resected non-small cell lung cancer. Lung Cancer, 2005, 49, 325-335.	0.9	159
14	Cancer Incidence Among Patients of the U.S. Veterans Affairs Health Care System. Military Medicine, 2012, 177, 693-701.	0.4	153
15	Human Nonsyndromic Hereditary Deafness DFNA17 Is Due to a Mutation in Nonmuscle Myosin MYH9. American Journal of Human Genetics, 2000, 67, 1121-1128.	2.6	152
16	Mouse models of MYH9-related disease: mutations in nonmuscle myosin II-A. Blood, 2012, 119, 238-250.	0.6	151
17	Cisplatin and Etoposide Versus Carboplatin and Paclitaxel With Concurrent Radiotherapy for Stage III Nonâ€“Small-Cell Lung Cancer: An Analysis of Veterans Health Administration Data. Journal of Clinical Oncology, 2015, 33, 567-574.	0.8	114
18	Antitumor Activity of a Monoclonal Antibody Directed Against Gastrin-Releasing Peptide in Patients With Small Cell Lung Cancer. Chest, 1997, 112, 256-261.	0.4	103

#	Article	IF	Citations
19	Cancer Incidence Among Patients of the U.S. Veterans Affairs Health Care System: 2010 Update. Military Medicine, 2017, 182, e1883-e1891.	0.4	98
20	Genetic Analysis of the Â-Tubulin Gene, TUBB, in Non-Small-Cell Lung Cancer. Journal of the National Cancer Institute, 2001, 93, 1886-1888.	3.0	89
21	Carbonic Anhydrase IX in Early-Stage Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2004, 10, 7925-7933.	3.2	87
22	Genotype-phenotype correlation in MYH9-related thrombocytopenia. British Journal of Haematology, 2005, 130, 620-627.	1.2	86
23	Differential Inactivation of CDKN2 and Rb Protein in Non–Small-Cell and Small-Cell Lung Cancer Cell Lines. Journal of the National Cancer Institute, 1995, 87, 756-761.	3.0	81
24	Persistent Smoking After a Diagnosis of Lung Cancer Is Associated With Higher Reported Pain Levels. Journal of Pain, 2009, 10, 323-328.	0.7	81
25	Rod mutations associated with MYH9-related disorders disrupt nonmuscle myosin-IIA assembly. Blood, 2005, 105, 161-169.	0.6	79
26	Familial Chordoma, a Tumor of Notochordal Remnants, Is Linked to Chromosome 7q33. American Journal of Human Genetics, 2001, 69, 454-460.	2.6	71
27	MEN1 gene mutation analysis of high-grade neuroendocrine lung carcinoma. , 2000, 28, 58-65.		68
28	Assessment of the Scope and Quality of Clinical Practice Guidelines in Lung Cancer*. Chest, 2003, 123, 7S-20S.	0.4	66
29	Quality of Nonmetastatic Colorectal Cancer Care in the Department of Veterans Affairs. Journal of Clinical Oncology, 2010, 28, 3176-3181.	0.8	61
30	Impact of Race on Treatment and Survival among U.S. Veterans with Early-Stage Lung Cancer. Journal of Thoracic Oncology, 2016, 11, 1672-1681.	0.5	60
31	Fluorescence in situ hybridization analysis of keratinocyte growth factor gene amplification and dispersion in evolution of great apes and humans. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 11461-11465.	3.3	56
32	Molecular classification and molecular genetics of human lung cancers. Seminars in Oncology, 2004, 31, 4-19.	0.8	56
33	Molecular Characterization of Putative Chordoma Cell Lines. Sarcoma, 2010, 2010, 1-14.	0.7	56
34	Characterization of T gene sequence variants and germline duplications in familial and sporadic chordoma. Human Genetics, 2014, 133, 1289-1297.	1.8	54
35	Direct Myocardial Effects of Intracoronary Administration of New Contrast Materials with Low Osmolality. Investigative Radiology, 1980, 15, 39-46.	3.5	50
36	A Phase II Study of Dasatinib in Patients with Chemosensitive Relapsed Small Cell Lung Cancer (Cancer) Tj ETQq0 0 0 rgBT /Overlock 10	0.5	46

#	Article	IF	Citations
37	Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy. Clinical Cancer Research, 2016, 22, 4890-4900.	3.2	46
38	Developing and Sustaining Quality Improvement Partnerships in the VA: The Colorectal Cancer Care Collaborative. Journal of General Internal Medicine, 2010, 25, 38-43.	1.3	44
39	Methylthioadenosine phosphorylase and activated insulinâ€like growth factorâ€1 receptor/insulin receptor: potential therapeutic targets in chordoma. Journal of Pathology, 2010, 220, 608-617.	2.1	41
40	CDKN2 in HPV-positive and HPV-negative cervical-carcinoma cell lines. International Journal of Cancer, 1995, 63, 226-230.	2.3	40
41	Treatment Outcomes of Different Prognostic Groups of Patients on Cancer and Leukemia Group B Trial 39801: Induction Chemotherapy Followed by Chemoradiotherapy Compared with Chemoradiotherapy Alone for Unresectable Stage III Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2009, 4, 1117-1125.	0.5	40
42	A National Survey of Pulmonologistsâ€™ Views on Low-Dose CT Screening for Lung Cancer. Annals of the American Thoracic Society, 2015, 12, 1667-75.	1.5	40
43	Cisplatin versus Carboplatin-Based Regimens for the Treatment of Patients with Metastatic Lung Cancer. An Analysis of Veterans Health Administration Data. Journal of Thoracic Oncology, 2014, 9, 702-709.	0.5	39
44	Mutation ofp53 gene in hepatocellular carcinoma cell lines with HBX DNA. , 1996, 67, 898-902.		37
45	Overview of Genetic and Molecular Events in the Pathogenesis of Lung Cancer. Chest, 1993, 103, 1S-3S.	0.4	36
46	Prevention of Lung Cancer*. Chest, 2003, 123, 50S-59S.	0.4	36
47	Induction chemotherapy followed by concomitant chemoradiotherapy (CT/XRT) versus CT/XRT alone for regionally advanced unresectable non-small cell lung cancer (NSCLC): Initial analysis of a randomized phase III trial. Journal of Clinical Oncology, 2004, 22, 7005-7005.	0.8	36
48	Influence of Comorbidity on Racial Differences in Receipt of Surgery Among US Veterans With Early-Stage Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2013, 31, 475-481.	0.8	35
49	Safety and Efficacy of Weekly Oral Oltipraz in Chronic Smokers. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 892-899.	1.1	34
50	Use and impact of adjuvant chemotherapy in patients with resected nonâ€small cell lung cancer. Cancer, 2014, 120, 1939-1947.	2.0	34
51	Emergence of the keratinocyte growth factor multigene family during the great ape radiation.. Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 9287-9291.	3.3	33
52	Nonmyeloablative stem cell transplantation: reduced-intensity conditioning for cancer immunotherapyâ€”from bench to patient bedside. Seminars in Oncology, 2004, 31, 4-21.	0.8	33
53	Colorectal Cancer Statistics From the Veterans Affairs Central Cancer Registry. Clinical Colorectal Cancer, 2016, 15, e199-e204.	1.0	33
54	RitterazineÂB, a new cytotoxic natural compound, induces apoptosis in cancer cells. Cancer Chemotherapy and Pharmacology, 2003, 51, 202-208.	1.1	32

#	Article	IF	Citations
55	Identification of repurposed small molecule drugs for chordoma therapy. Cancer Biology and Therapy, 2013, 14, 638-647.	1.5	32
56	Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castrationâ€resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance). Cancer, 2015, 121, 1025-1031.	2.0	32
57	Effect of age on the efficacy of adjuvant chemotherapy for resected nonâ€“small cell lung cancer. Cancer, 2015, 121, 2578-2585.	2.0	31
58	Improved Survival of Stage I Nonâ€“Small Cell Lung Cancer: A VA Central Cancer Registry Analysis. Journal of Thoracic Oncology, 2017, 12, 1814-1823.	0.5	31
59	Corroboration of a familial chordoma locus on chromosome 7q and evidence of genetic heterogeneity using single nucleotide polymorphisms (SNPs). International Journal of Cancer, 2005, 116, 487-491.	2.3	30
60	Lung Cancer Chemoprevention. Chest, 2007, 132, 56S-68S.	0.4	30
61	Cancer Incidence in HIV-Infected Versus Uninfected Veterans: Comparison of Cancer Registry and ICD-9 Code Diagnoses. Journal of AIDS & Clinical Research, 2014, 05, 1000318.	0.5	30
62	MYH9 E1841K Mutation Augments Proteinuria and Podocyte Injury and Migration. Journal of the American Society of Nephrology: JASN, 2018, 29, 155-167.	3.0	30
63	Metformin, Diabetes, and Survival among U.S. Veterans with Colorectal Cancer. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 1418-1425.	1.1	28
64	Small cell lung carcinoma cell lines express mRNA for calcitonin and alpha- and beta-calcitonin gene related peptides. Cancer Letters, 1994, 81, 19-25.	3.2	27
65	Retrospective family study of childhood medulloblastoma. American Journal of Medical Genetics, Part A, 2005, 134A, 399-403.	0.7	27
66	TP53 andRAS mutations in metachronous tumors from patients with cancer of the upper aerodigestive tract. International Journal of Cancer, 1995, 64, 229-233.	2.3	25
67	Paclitaxel by 96-hour continuous infusion in combination with cisplatin: a phase I trial in patients with advanced lung cancer.. Journal of Clinical Oncology, 1997, 15, 735-743.	0.8	24
68	Retreatment of Patients Surviving Cancer-Free 2 or More Years After Initial Treatment of Small Cell Lung Cancer. Chest, 1996, 110, 165-171.	0.4	23
69	Co-amplification of a novel cyclophilin-like gene (PPIE) with L-myc in small cell lung cancer cell lines. Oncogene, 1998, 17, 1019-1026.	2.6	23
70	Phase II Study of Induction Cisplatin and Irinotecan Followed by Concurrent Carboplatin, Etoposide, and Thoracic Radiotherapy for Limited-Stage Small-Cell Lung Cancer, CALGB 30206. Journal of Thoracic Oncology, 2013, 8, 102-108.	0.5	23
71	Real World Outcomes versus Clinical Trial Results of Durvalumab Maintenance in Veterans with Stage III Non-Small Cell Lung Cancer. Cancers, 2022, 14, 614.	1.7	23
72	Assessment of the Impact of Adjunctive Proactive Telephone Counseling to Promote Smoking Cessation among Lung Cancer Patients' Social Networks. American Journal of Health Promotion, 2013, 27, 181-190.	0.9	20

#	Article	IF	Citations
73	Comparison of Annotation Services for Next-Generation Sequencing in a Large-Scale Precision Oncology Program. JCO Precision Oncology, 2020, 4, 212-221.	1.5	19
74	Calcitonin elevation in small cell lung cancer without ectopic production.. American Journal of Respiratory and Critical Care Medicine, 1994, 149, 183-190.	2.5	18
75	Proactive recruitment of cancer patients' social networks into a smoking cessation trial. Contemporary Clinical Trials, 2011, 32, 498-504.	0.8	18
76	Impact of a Multidisciplinary Thoracic Oncology Clinic on the Timeliness of Care. Journal of Thoracic Oncology, 2006, 1, 692-696.	0.5	17
77	Molecular characterization of chordoma xenografts generated from a novel primary chordoma cell source and two chordoma cell lines. Journal of Neurosurgery: Spine, 2014, 21, 386-393.	0.9	17
78	Phase II Study of Dasatinib in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer. Cancer Investigation, 2017, 35, 32-35.	0.6	17
79	Autosomal dominant macrothrombocytopenia with leukocyte inclusions (May-Hegglin anomaly) is linked to chromosome 22q12-13. Human Genetics, 2000, 106, 557-564.	1.8	16
80	BRCA testing within the Department of Veterans Affairs: concordance with clinical practice guidelines. Familial Cancer, 2017, 16, 41-49.	0.9	16
81	Veterans Affairs Pharmacogenomic Testing for Veterans (PHASER) clinical program. Pharmacogenomics, 2021, 22, 137-144.	0.6	16
82	Phosphorylated epidermal growth factor receptor and cyclooxygenase-2 expression in localized non-small cell lung cancer. Medical Oncology, 2010, 27, 91-97.	1.2	15
83	Readiness for Implementation of Lung Cancer Screening: A National Survey of VA Pulmonologists. Annals of the American Thoracic Society, 2016, 13, 1794-1801.	1.5	15
84	Effects of intracoronary administration of contrast materials on left ventricular function in the presence of severe coronary artery stenosis. CardioVascular and Interventional Radiology, 1981, 4, 110-116.	0.9	14
85	A Preliminary Exploration of College Smokersâ€™ Reactions to Nicotine Dependence Genetic Susceptibility Feedback. Nicotine and Tobacco Research, 2015, 17, 337-343.	1.4	14
86	Racial Differences in Treatment and Survival among Veterans and Non-Veterans with Stage I NSCLC: An Evaluation of Veterans Affairs and SEER-Medicare Populations. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 112-118.	1.1	14
87	Correlation of expression of bombesin-like peptides and receptors with growth inhibition by an anti-bombesin antibody in small-cell lung cancer cell lines1The opinions or assertions contained herein are the private views of the authors and are not to be construed as official or as reflecting the views of the Department of the Navy or the Department of Defense. This is a US Government work. There are no restrictions on its use.1. Lung Cancer, 1998, 21, 165-175.	0.9	13
88	Genomic structure of theEPHA1receptor tyrosinekinase gene. Molecular and Cellular Probes, 1999, 13, 169-173.	0.9	13
89	Clinical decisions surrounding genomic and proteomic testing among United States veterans treated for lung cancer within the Veterans Health Administration. BMC Medical Informatics and Decision Making, 2017, 17, 71.	1.5	12
90	Once Versus Twice Daily Fractionation for Limited Stage SCLC. International Journal of Radiation Oncology Biology Physics, 2017, 99, E442.	0.4	11

#	Article	IF	Citations
91	Increasing PET Use in Small Cell Lung Cancer: Survival Improvement and Stage Migration in the VA Central Cancer Registry. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 127-139.	2.3	11
92	Veterans health administration hepatitis B testing and treatment with anti-CD20 antibody administration. World Journal of Gastroenterology, 2016, 22, 4732.	1.4	11
93	Biology of small cell lung cancer. Lung Cancer, 1995, 12, S5-S16.	0.9	10
94	Phase II study of carboplatin, irinotecan, and thalidomide combination in patients with extensive stage small-cell lung cancer. Lung Cancer, 2006, 54, 431-432.	0.9	10
95	Epidermal Growth Factor Receptor Mutational Testing and Erlotinib Treatment Among Veterans Diagnosed With Lung Cancer in the United States Department of Veterans Affairs. Clinical Lung Cancer, 2017, 18, 401-409.	1.1	10
96	Genetic Changes in Contralateral Bronchioloalveolar Carcinomas of the Lung. Oncology, 2001, 60, 81-87.	0.9	9
97	Acting in the Face of Uncertainty. Annals of Internal Medicine, 2014, 161, 300.	2.0	9
98	Precision Medicine for CRC Patients in the Veteran Population: State-of-the-Art, Challenges and Research Directions. Digestive Diseases and Sciences, 2018, 63, 1123-1138.	1.1	9
99	Role of adjuvant chemotherapy following chemoradiation and surgery for locoregionally advanced rectal cancer: A Veterans Health Administration analysis.. Journal of Clinical Oncology, 2018, 36, 741-741.	0.8	9
100	Autosomal dominant macrothrombocytopenia with leukocyte inclusions (May-Hegglin anomaly) is linked to chromosome 22q12-13. Human Genetics, 2000, 106, 557-564.	1.8	8
101	Comparing a medical records-based and a claims-based index for measuring comorbidity in patients with lung or colon cancer. Journal of Geriatric Oncology, 2015, 6, 202-210.	0.5	8
102	National Trends in End-of-Life Care for Veterans With Advanced Cancer in the Veterans Health Administration: 2009 to 2016. Journal of Oncology Practice, 2019, 15, e568-e575.	2.5	8
103	Transportation as a barrier to colorectal cancer care. BMC Health Services Research, 2021, 21, 332.	0.9	8
104	Barriers to Prescribing Targeted Therapies for Patients With NSCLC With Highly Actionable Gene Variants in the Veterans Affairs National Precision Oncology Program. JCO Oncology Practice, 2021, 17, e1012-e1020.	1.4	8
105	De-escalating adjuvant durvalumab treatment duration in stage III non-small cell lung cancer. European Journal of Cancer, 2022, 171, 55-63.	1.3	8
106	Oncogenic mutations in ras create HLA-A2.1 binding peptides but affect their extracellular antigen processing. International Immunology, 1997, 9, 1085-1093.	1.8	7
107	Genomic Analysis of Metastatic Solid Tumors in Veterans: Findings From the VHA National Precision Oncology Program. JCO Precision Oncology, 2019, 3, 1-13.	1.5	7
108	Cancer Among Women Treated in the Veterans Affairs Healthcare System. Journal of Women's Health, 2019, 28, 268-275.	1.5	7

#	Article	IF	Citations
109	Survival Advantage With Adjuvant Chemotherapy for Locoregionally Advanced Rectal Cancer: A Veterans Health Administration Analysis. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 52-58.	2.3	7
110	Preventing Hepatitis B Reactivation During Antiâ€CD20 Antibody Treatment in the Veterans Health Administration. Hepatology Communications, 2018, 2, 1136-1146.	2.0	6
111	Chronic disease management perspectives of colorectal cancer survivors using the Veterans Affairs healthcare system: a qualitative analysis. BMC Health Services Research, 2018, 18, 171.	0.9	6
112	Cost-Effectiveness of Tumor Genomic Profiling to Guide First-Line Targeted Therapy Selection in Patients With Metastatic Lung Adenocarcinoma. Value in Health, 2022, 25, 582-594.	0.1	6
113	Medical oncologistsâ€™ perspectives of the Veterans Affairs National Precision Oncology Program. PLoS ONE, 2020, 15, e0235861.	1.1	5
114	Genomic analysis of metastatic solid tumors in veterans: Findings from the VHA National Precision Oncology Program.. Journal of Clinical Oncology, 2019, 37, 3074-3074.	0.8	5
115	Second line treatment of small cell lung cancer: more is better?. Annals of Translational Medicine, 2016, 4, S65-S65.	0.7	5
116	Evaluation of the Veterans Affairs Pharmacogenomic Testing for Veterans (PHASER) clinical program at initial test sites. Pharmacogenomics, 2021, 22, 1121-1133.	0.6	5
117	Etiology of the Mutational Spectrum of ras Genes in Human Carcinomas. Journal of the National Cancer Institute, 2002, 94, 1516-1517.	3.0	4
118	Comparison of Quality Oncology Practice Initiative (QOPI) Measure Adherence Between Oncology Fellows, Advanced Practice Providers, and Attending Physicians. Journal of Cancer Education, 2015, 30, 774-778.	0.6	4
119	Clinical Impact of 21-Gene Recurrence Score Test Within the Veterans Health Administration: Utilization and Receipt of Guideline-Concordant Care. Clinical Breast Cancer, 2018, 18, 135-143.	1.1	4
120	Long-term Clinical Outcomes of Nonoperative Management With Chemoradiotherapy for Locally Advanced Rectal Cancer in the Veterans Health Administration. International Journal of Radiation Oncology Biology Physics, 2019, 103, 565-573.	0.4	4
121	Biology and Molecular Genetics of Lung Cancer. Seminars in Respiratory and Critical Care Medicine, 1996, 17, 299-308.	0.8	3
122	Evolution of the Quality Oncology Practice Initiative Supportive Care Quality Measures Portfolio and Conformance at a Veterans Affairs Medical Center. Journal of Oncology Practice, 2013, 9, e86-e89.	2.5	3
123	Cardiovascular disease-related chronic conditions among Veterans Affairs nonmetastatic colorectal cancer survivors: a matched caseâ€“control analysis . Cancer Management and Research, 2019, Volume 11, 6793-6802.	0.9	3
124	Chemoradiation treatment patterns among United States Veteran Health Administration patients with unresectable stage III non-small cell lung cancer. BMC Cancer, 2021, 21, 824.	1.1	3
125	Implementation of precision oncology in the Veterans Health Administration (VHA).. Journal of Clinical Oncology, 2017, 35, 6507-6507.	0.8	3
126	Integration of Patient-Reported Outcome Measures in the Electronic Health Record: The Veterans Affairs Experience. JCO Clinical Cancer Informatics, 2022, 6, e2100086.	1.0	3

#	Article	IF	Citations
127	Surveillance for Hepatocellular Carcinoma. Annals of Internal Medicine, 2011, 155, 274.	2.0	2
128	Survival With Stereotactic Body Radiation Therapy (SBRT) and Conventional Radiation Therapy (CRT) in Stage I Non-Small Cell Lung Cancer Patients in the Veterans Affairs System. International Journal of Radiation Oncology Biology Physics, 2016, 96, S9.	0.4	2
129	Impact of race on early-stage lung cancer treatment and survival.. Journal of Clinical Oncology, 2012, 30, 232-232.	0.8	2
130	The Veterans Health Administration Precision Oncology Program for Advanced Prostate Cancer Patients: Expanding tumor NGS opportunities to a broader patient population.. Journal of Clinical Oncology, 2019, 37, 193-193.	0.8	2
131	Cost-effectiveness of genomic profiling in veterans with metastatic lung adenocarcinoma.. Journal of Clinical Oncology, 2020, 38, 7075-7075.	0.8	2
132	Erythropoietin and Erythropoietin Receptor Expression in Early Stage Non-Small Cell Lung Cancer: Prognostic Significance.. Blood, 2005, 106, 4258-4258.	0.6	2
133	Homologous Recombination Repair Gene Variants and Outcomes Among Patients With Prostate Cancer Treated With Poly (ADP-ribose) Polymerase Inhibitors. JCO Precision Oncology, 2022, 6, e2100461.	1.5	2
134	Anticancer antibodies for lung cancer.. Journal of Clinical Oncology, 1994, 12, 2519-2520.	0.8	1
135	Feasibility of using an epigenetic marker of risk for lung cancer, methylation of p16, to promote smoking cessation among US veterans. BMJ Open Respiratory Research, 2014, 1, e000032.	1.2	1
136	Uptake of KRAS Testing and Anti-EGFR Antibody Use for Colorectal Cancer in the VA. JCO Precision Oncology, 2021, 5, 638-645.	1.5	1
137	Real-world outcomes among prostate cancer patients with BRCA2 gene variants compared to variants in other homologous DNA repair genes.. Journal of Clinical Oncology, 2021, 39, e17033-e17033.	0.8	1
138	EGFR mutation testing and TKI treatment patterns among veterans with stage III and IV non-small cell lung cancer. Cancer Treatment and Research Communications, 2021, 27, 100327.	0.7	1
139	VA Cancer Research: A Legacy and A Future. Seminars in Oncology, 2019, 46, 305-307.	0.8	1
140	Improving quality at university based hematology/oncology fellowship continuity clinic with the quality oncology practice initiative (QOPI). Journal of Clinical Oncology, 2008, 26, 6578-6578.	0.8	1
141	Association between metformin (M) use and survival among non-small cell lung cancer (NSCLC) patients (pts).. Journal of Clinical Oncology, 2014, 32, 7568-7568.	0.8	1
142	Colorectal cancer survivorship statistics: A Veterans Affairs Central Cancer Registry analysis.. Journal of Clinical Oncology, 2016, 34, e267-e267.	0.8	1
143	National trends in end of life care for veterans with advanced cancer.. Journal of Clinical Oncology, 2018, 36, 3-3.	0.8	1
144	An NLP tool to identify molecular diagnostic testing in veterans with stage IV NSCLC.. Journal of Clinical Oncology, 2019, 37, 318-318.	0.8	1

#	Article	IF	Citations
145	Persistence of quality improvement in a Veterans Affairs (VA) academic practice assessed by Quality Oncology Practice Initiative (QOPI).. Journal of Clinical Oncology, 2012, 30, 209-209.	0.8	1
146	Barriers to prescribing targeted therapies for NSCLC patients with highly actionable gene variants in the VA National Precision Oncology Program.. Journal of Clinical Oncology, 2020, 38, 2005-2005.	0.8	1
147	Analysis of actionable genetic alterations in lung carcinoma from the VA National Precision Oncology Program. Seminars in Oncology, 2022, , .	0.8	1
148	P-339 Multidisciplinary versus traditional evaluation in sequentialpatient cohorts with lung cancer. Lung Cancer, 2005, 49, S205.	0.9	0
149	Mouse Models of Human MYH9-Related Diseases. Biophysical Journal, 2011, 100, 594a-595a.	0.2	0
150	Adjuvant Chemotherapy for Older Patients With Early-Stage Non-Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2014, 90, S12-S13.	0.4	0
151	Outcome Analysis of Treatment in Stage IIA, T3N0 Rectal Adenocarcinoma in the Veterans Health Administration (VHA). International Journal of Radiation Oncology Biology Physics, 2016, 96, E186.	0.4	0
152	CLINICAL IMPACT OF THE 21-GENE RS TEST WITHIN THE VETERANS HEALTH CARE ADMINISTRATION. Value in Health, 2016, 19, A312.	0.1	0
153	Metformin, Diabetes, and Survival among U.S. Veterans with Colorectal Cancerâ€"Response. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 977-977.	1.1	0
154	Non-operative Management for Locally Advanced Rectal Cancer in the Veterans Health Administration. International Journal of Radiation Oncology Biology Physics, 2017, 99, S67-S68.	0.4	0
155	Modeling and Prediction of SIB Prostate IMRT Plans. International Journal of Radiation Oncology Biology Physics, 2018, 102, e541.	0.4	0
156	Cancer specialists in the VA as early adopters of clinical genetic services.. Journal of Clinical Oncology, 2021, 39, 11029-11029.	0.8	0
157	Suicide risk following a new cancer diagnosis among veterans in Veterans Health Administration care.. Journal of Clinical Oncology, 2021, 39, 12130-12130.	0.8	0
158	Automated extraction of Quality Oncology Practice Initiative (QOPI) quality measures from the Veterans Health Administration (VHA) electronic health record system.. Journal of Clinical Oncology, 2011, 29, e16560-e16560.	0.8	0
159	The evolution of supportive care quality measures portfolio and conformance.. Journal of Clinical Oncology, 2012, 30, 259-259.	0.8	0
160	Abstract 352: Murine model of chordoma: Sonic Hedgehog promoter-driven Cre activation of Brachyury (T) expression induces spinal disk abnormalities and perinatal lethal developmental defects.. , 2013, , .		0
161	Comparison of QOPI measure conformance between oncology fellows and attending physicians.. Journal of Clinical Oncology, 2013, 31, 162-162.	0.8	0
162	Tools to accurately identify veterans who undergo molecular diagnostic testing.. Journal of Clinical Oncology, 2013, 31, 201-201.	0.8	0

#	Article	IF	Citations
163	Metformin (M), diabetes (DM), and colorectal cancer (CRC) survival among U.S. veterans.. Journal of Clinical Oncology, 2014, 32, 3535-3535.	0.8	0
164	A genome-wide association study (GWAS) of docetaxel-induced neutropenia in CALGB 90401/60404 (Alliance).. Journal of Clinical Oncology, 2014, 32, 9612-9612.	0.8	0
165	Epidermal growth factor receptor (EGFR) testing among veterans diagnosed with lung cancer in the VA.. Journal of Clinical Oncology, 2015, 33, e17582-e17582.	0.8	0
166	Utilization of BRCA1/BRCA2 testing in Veterans Health Administration.. Journal of Clinical Oncology, 2015, 33, e17510-e17510.	0.8	0
167	Implementation of gene expression testing for breast cancer patients within the Veterans Health Administration.. Journal of Clinical Oncology, 2015, 33, e17511-e17511.	0.8	0
168	Abstract 2037: A discovery study to identify clinical and genetic risk factors for bevacizumab (BEV)-related gastrointestinal (GI) hemorrhage (HEM) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated on CALGB 90401 (Alliance). , 2016, , .		0
169	Short- and long-term outcomes of early stage non-small cell lung cancer (NSCLC) surgery.. Journal of Clinical Oncology, 2017, 35, 8544-8544.	0.8	0
170	Cardiovascular disease-related chronic conditions among Veterans Affairs colorectal cancer survivors: A matched case-control analysis.. Journal of Clinical Oncology, 2018, 36, 4-4.	0.8	0
171	Association of NGS mutational pattern with immune checkpoint inhibitor clinical benefit in solid tumors.. Journal of Clinical Oncology, 2018, 36, e24274-e24274.	0.8	0
172	Improved survival of small cell lung cancer in the veterans health administration from 2000-2010: Association with increasing utilization of PET staging.. Journal of Clinical Oncology, 2018, 36, e20571-e20571.	0.8	0
173	Implementation of the VA Symptom Assessment Scale (VSAS): Five-year experience.. Journal of Clinical Oncology, 2019, 37, e23120-e23120.	0.8	0
174	Abstract PR11: Racial differences in characteristics of early- vs. late-onset colorectal cancer among veterans. , 2020, , .		0
175	VA National Precision Oncology Program. , 2020, 37, S22-S27.		0
176	Cancer Care Collaborative Approach to Optimize Clinical Care. Federal Practitioner: for the Health Care Professionals of the VA, DoD, and PHS, 2017, 34, S42-S49.	0.6	0
177	Recommendation on Advanced Molecular Testing in Hematolymphoid Malignancies in the Veterans Population. Blood, 2021, 138, 4983-4983.	0.6	0
178	Integrating Medical Genetics Into Precision Oncology Practice in the Veterans Health Administration: The Time Is Now. JCO Oncology Practice, 2022, , OP2100693.	1.4	0
179	Clinical markers of successful liquid biopsy-based genomic profiling in veterans with prostate cancer.. Journal of Clinical Oncology, 2022, 40, e17031-e17031.	0.8	0
180	Frequency and outcomes of molecularly guided off-label targeted agent prescriptions in the VA National Precision Oncology Program (NPOP).. Journal of Clinical Oncology, 2022, 40, e18676-e18676.	0.8	0